The transcriptional co-activator YAP controls cell proliferation, survival, and tissue regeneration in response to changes in the mechanical environment. It is not known how mechanical stimuli such as tension are sensed and how the signal is transduced to control YAP activity. Here we show that the LIM domain protein TRIP6 acts as part of a mechanotransduction pathway at adherens junctions to promote YAP activity by inhibiting the LATS1/2 kinases. Previous studies showed that vinculin at adherens junctions becomes activated by mechanical tension. We show that vinculin inhibits Hippo signaling by recruiting TRIP6 to adherens junctions and stimulating its binding to and inhibition of LATS1/2 in response to tension. TRIP6 competes with MOB1 for binding to LATS1/2 thereby blocking MOB1 from recruiting the LATS1/2 activating kinases MST1/2. Together these findings reveal a novel mechanotransduction cascade that transduces tension signals sensed at adherens junctions to control Hippo pathway signaling.
Introduction
Tissue architecture and mechanical forces are major regulators of cell proliferation, and they play important roles during development, organ growth, and tissue regeneration (Heller and Fuchs, 2015; Huang and Ingber, 1999; Mammoto et al., 2013) . The cytoskeleton, extracellular matrix, and cell-cell adhesion are critical for transmitting force between cells and across tissues (Vogel and Sheetz, 2006) . The Hippo signaling pathway is a major regulator of cellular responses to mechanical inputs (Halder et al., 2012; Sun and Irvine, 2016) . The core Hippo pathway (Meng et al., 2016) consists of two kinase modules: the first includes several Ste20-superfamily kinases (MST1/2 are the best characterized), which phosphorylate and activate the LATS1/2 kinases. MST1/2 phosphorylation of LATS1/2 is mediated by MOB1, which promotes association of MST1/2 with LATS1/2. LATS1/2 then phosphorylate and inhibit the transcriptional co-activator YAP (and its homolog TAZ) by causing it to be sequestered in the cytoplasm or degraded. When in the nucleus, YAP associates with transcription factor TEAD to upregulate genes responsible for survival, proliferation, and stem cell maintenance. The growth promoting properties of YAP are frequently co-opted by cancer cells, in which YAP is often activated and overexpressed (Yu et al., 2015) . Although the activity of both LATS1/2 and YAP are clearly regulated by mechanical inputs, how those inputs are sensed and the signals are transduced remain obscure.
Experiments in Drosophila and mammalian cells revealed that Hippo pathway regulation of YAP is controlled by mechanical tension (Aragona et al., 2013; Benham-Pyle et al., 2015; Codelia et al., 2014; Rauskolb et al., 2014) . When cells experience high mechanical tension, YAP localizes to the nucleus and promotes cell proliferation. Conversely, low tension causes YAP to exit the nucleus and cells to arrest growth. Transmission of tension across tissues requires cell-cell adhesion such as that provided by cadherins (Mui et al., 2016) . Tension experienced by cells can be generated by the cells themselves through actomyosin stress fibers or by externally imposed stretch or force (Halder et al., 2012) . Studies in Drosophila indicate that tension within tissues decreases as cell density increases, and hence tension sensing could contribute to densitydependent inhibition of cell growth, a property that is typically lost in cancer cells (Rauskolb et al., 2014) . Perturbation of stress fibers, externally applied stretch, and cell density all modulate LATS1/2 and YAP activity; however, the sensors are not known. In Drosophila, the LIM domain protein Ajuba inhibits Warts (the LATS1/2 homolog) and recruits it to adherens junctions in a tension-dependent manner (Rauskolb et al., 2014) . The mechanism by which Ajuba regulates Warts activity is not clearly understood, and reports have differed regarding whether Ajuba-related proteins function similarly in mammals (Codelia et al., 2014; Jagannathan et al., 2016) . Here we show that the human LIM domain protein TRIP6 acts as part of a mechanotransduction cascade at adherens junctions to regulate LATS1/2 in response to mechanical tension at cell-cell junctions.
RESULTS

TRIP6 activates YAP through inhibition of LATS1/2
Although TRIP6 is overexpressed in various cancers where it promotes proliferation and invasion (Chastre et al., 2009; Fei et al., 2013; Grunewald et al., 2013) , prior studies had not connected TRIP6 to the Hippo signaling pathway. We previously identified TRIP6 as one of several LATS2 binding partners using tandem affinity purification and mass spectrometry (Paramasivam et al., 2011) . Here, to validate the LATS2-TRIP6 interaction, we performed coimmunoprecipitation experiments. LATS2 was pulled down in TRIP6 immunoprecipitates when both proteins were overexpressed ( Figure 1A ). In addition, endogenous LATS1 was present in TRIP6 immune complexes isolated from MCF10A cells ( Figure 1B ). Like its related family members (Zyxin, LPP, Ajuba, WTIP, and LIMD1), the carboxy-terminal half of TRIP6 consists of 3 conserved LIM domains ( Figure 1A) . Truncation experiments showed that LATS2 binding maps to the C-terminal LIM domain half of TRIP6 ( Figure 1A) . We next tested which parts of LATS2 interacted with TRIP6. TRIP6 bound to the Nterminal region of LATS2 and specifically interacted with two segments (amino acids 376-397 and 625-644) ( Figure 1C ). This finding is highly reminiscent of previous findings with Ajuba and Zyxin (Abe et al., 2006; Hirota et al., 2000) .
To determine whether TRIP6 regulates LATS1/2 activity, we examined the effects of TRIP6 overproduction and loss of function. Overproduction of TRIP6 in HEK293A cells reduced endogenous LATS1/2 activity as judged by probing the two sites of activating phosphorylation on LATS1/2, T1079 and S909 (for LATS1, T1041 and S872 for LATS2) ( Figure 1D & F) (note that T1079 is phosphorylated by MST1/2 and S909 is an autophosphorylation site). In contrast, TRIP6 overexpression did not affect MST2 activating phosphorylation ( Figure 1H ), suggesting that TRIP6 may regulate the ability of LATS1/2 to be phosphorylated by MST1/2. CRISPR mediated deletion of TRIP6 in HEK293A cells (Figure 1E & G) or shRNA mediated knockdown of TRIP6 in MCF10A cells ( Figure S1A ) increased LATS1/2 activating phosphorylation levels. Together these results show that TRIP6 acts to inhibit LATS1/2 activity. Because LATS1/2 phosphorylate and inhibit YAP nuclear localization, stability, and activity, we tested the effect of modulating TRIP6 levels on YAP. Overexpression of TRIP6 in HEK293A cells inhibited LATS1/2 phosphorylation of YAP on S127 ( Figure 1D & F) and increased expression of YAP target genes ( Figure 1I ). In contrast, reduced levels of TRIP6 inhibited YAP function. Specifically, shRNA mediated knockdown of TRIP6 in MCF10A cells reduced expression of YAP target genes ( Figure S1B ), and diminished YAP nuclear localization ( Figure S1C ). These cells also had reduced levels of YAP protein ( Figure S1D ), presumably caused by LATS1/2 phosphorylation dependent degradation (Liu et al., 2010; Zhao et al., 2010) . TRIP6∆ HEK293A cells showed increased YAP S127 phosphorylation ( Figure 1E & G) , reduced expression of YAP target genes ( Figure 1J ), and reduced YAP nuclear localization ( Figure 1K ). Our observation that MCF10A, but not HEK293A, cells had reduced levels of YAP when TRIP6 was depleted (or eliminated) may reflect cell type differences in YAP degradation in response to LATS1/2 dependent phosphorylation. The TRIP6∆ HEK293A cells also displayed a defect in cell-cell adhesion as judged by the presence of frequent gaps between cells even at high density that were not observed in parental HEK293A cells ( Figure 1K , S1E). The cell-cell adhesion and YAP localization defect in TRIP6∆ HEK293A cells was rescued by reexpression of TRIP6 (Figure S1E-F). MCF10A cells knocked down for TRIP6 with shRNA did not show obvious cell-cell adhesion defects perhaps due to the presence of residual TRIP6. Overall, these results show that TRIP6 inhibition of LATS1/2 promotes YAP activity.
TRIP6 inhibits LATS1/2 by blocking binding to MOB1
We next investigated the mechanism for how TRIP6 inhibits LATS1/2. TRIP6-related LIM domain proteins have been shown to bind and inhibit LATS (Abe et al., 2006; Das Thakur et al., 2010; Hirota et al., 2000; Rauskolb et al., 2011; Rauskolb et al., 2014; Reddy and Irvine, 2013) , however, it is not clear how they regulate LATS1/2 activity. Although zyxin was shown to promote degradation of LATS1/2 in response to hypoxia (Jagannathan et al., 2016), we did not observe any changes in LATS1 levels when TRIP6 levels were altered suggesting that TRIP6 uses a different mechanism. Because one of the TRIP6 binding sites in LATS2 (amino acids 625-644) overlaps with the binding site for its activator MOB1 (amino acids 595-662) (Ni et al., 2015) , we wondered if TRIP6 and MOB1 compete for binding to LATS1/2. This mechanism would be consistent with our observations that TRIP6 inhibits the ability of MST1/2 to phosphorylate LATS1/2, because MOB1 activates LATS1/2 by promoting its association with and phosphorylation by MST1/2 (Ni et al., 2015) . We first examined if TRIP6 could inhibit LATS1/2-MOB1 binding in vivo. We found that TRIP6 overexpression reduced LATS2-MOB1A association in HEK293 cells (Figure 2A ). To determine whether TRIP6 directly competes with MOB1A for binding to LATS2, competition experiments were carried out using purified recombinant proteins. Initial results demonstrated that GST-TRIP6 bound directly to MBP-LATS2 but not MBP alone ( Figure 2B , compare lanes 1 and 3). Competition experiments showed that MOB1A could compete with TRIP6 for binding to LATS2. 6HIS-MOB1A bound to MBP-LATS2 and inhibited GST-TRIP6 binding, with the highest levels of MOB1A reducing TRIP6-LATS2 binding to background levels ( Figure 2B , lanes 3-6). Addition of non-specific competitor (BSA), at the same level as the highest amount of MOB1A used ( Figure S2 ), did not cause any reduction in TRIP6-LATS2 binding ( Figure 2B, lane 7) . Together these results show that that TRIP6 and MOB1 compete for binding to LATS2 and that TRIP6 likely inhibits LATS1/2 activity at least in part by blocking MOB1 binding.
TRIP6 modulates LATS1/2 activity and localization in response to tension at cell-cell junctions.
To investigate what regulatory inputs might control TRIP6 inhibition of LATS1/2, we examined the localization of each protein. Endogenous TRIP6 and LATS1 colocalize to cell-cell junctions in MCF10A ( Figure 3A , S3A) and to a lesser extent in HEK293A ( Figure S3B ) cells. Although we have been unable to find LATS2 antibodies capable of detecting the endogenous protein, GFP-LATS2 fusions also localize to cell-cell junctions (Paramasivam et al., 2011) . TRIP6 has been previously reported to localize to both cell-cell junctions (adherens junctions) (Guo et al., 2014) and to focal adhesions (Wang et al., 1999; Zhao et al., 1999) . Although we could faintly observe TRIP6 at focal adhesions in MCF10A cells at low density or at the edge of monolayers, at densities typically used in this study (confluent but still proliferating), TRIP6 was primarily at adherens junctions, and we saw little focal adhesion staining for TRIP6 or the focal adhesion marker FAK ( Figure S3C ). LATS1 was not observed at focal adhesions in MCF10A cells at any density (data not shown). We next assessed the mutual dependence of LATS1 and TRIP6 localization. Knockdown of TRIP6 in MCF10A cells ( Figure  3A ; S3D) reduced localization of LATS1 to cell junctions. Deletion of TRIP6 in HEK293A cells ( Figure S3B ) also caused reduced localization of LATS1 to cellcell junctions, although because of the reduced cell-cell adhesion in these cells, it is possible that effects on LATS1 localization could be due to defects in cell-cell junctions. When LATS1/2 were knocked down (depleted) in MCF10A cells, TRIP6 remained at cell-cell junctions ( Figure 3B ; S3E), but its localization was more punctate and less smooth, possibly reflecting a transition to a more mesenchymal state (Zhang et al., 2008) . Together these results show that TRIP6 and LATS1/2 affect each other's localization and that TRIP6 may recruit LATS1/2 to cell junctions.
We next examined whether recruitment of TRIP6 and LATS1 to cell junctions is regulated by stimuli that control LATS1/2 activity. Both TRIP6 and LATS1 localized to cell-cell junctions in cells that were confluent but still proliferating. However, in highly dense non-proliferating cells TRIP6 and LATS1 no longer localized to cell-cell junctions ( Figure 3C , S3B), despite unchanged levels of both proteins ( Figure 3D ). Interestingly we also observed a reduction in TRIP6-LATS1 binding in MCF10A cells at high cell density ( Figure 3D ), consistent with the increased LATS1/2 activity observed under these conditions (Meng et al., 2015) . How cell density controls TRIP6-LATS1/2 binding and localization is not clear. However, a study in Drosophila tissue showed that tension at cell-cell junctions is reduced as cell density increases (Rauskolb et al., 2014 ). Therefore, we tested whether increasing tension at cell-cell junctions in dense cultures would restore localization of TRIP6 and LATS1 to cell-cell junctions. To do this, we examined TRIP6 and LATS1 localization in dense cultures grown on flexible PDMS substrates before and after static stretch for 2 hours. We observed that stretch increased TRIP6-LATS1 binding ( Figure 3E ), localization of both proteins to cellcell junctions ( Figure 3F ), and YAP activity ( Figure S3F ). Both tension dependent recruitment of LATS1 to cell-cell junctions and YAP activation in dense monolayers following stretch depended on TRIP6 ( Figure 3G -H). Together these results show that tension can trigger YAP activation through TRIP6 by increasing TRIP6 recruitment to cell-cell junctions, and TRIP6 binding to LATS1.
We also tested whether loss of tension across confluent (but not dense) monolayers of cells could trigger loss of LATS1-TRIP6 binding and colocalization at cell-cell junctions. Treatments that inhibit stress fibers such as type II myosin inhibition (Blebbistatin), Rho kinase inhibition (Y27632), or serum starvation are known to reduce tension at cell junctions (Yonemura et al., 2010) . All of these treatments inhibited both LATS1-TRIP6 binding and cell-cell junction localization, as did complete elimination of F-actin using Latrunculin B ( Figure  4A -C, S4A). These treatments (with the exception of Latrunculin B) did not obviously affect cell-cell adhesion and E-cadherin localization ( Figure S4B ). To reduce tension at cell junctions by blocking force transmission between cells, we disrupted cadherin complexes by treating cells with EGTA and found that this treatment also inhibited LATS1-TRIP6 binding and localization to cell-cell junctions ( Figure 4A -C, S4A). Together these observations suggest that TRIP6 responds to tension at cell-cell junctions to regulate LATS1 and YAP activity.
TRIP6 is a part of the mechanosensory complex at adherens junctions
We next investigated whether TRIP6 could be part of a mechano-sensing complex at cadherin-catenin based adherens junctions (Huveneers and de Rooij, 2013) . Previous studies showed that TRIP6 localizes to adherens junctions, and its association with the cadherin complex is dependent on engagement between the extra-cellular domains of cadherins on neighboring cells (Guo et al., 2014) . How TRIP6 interacts with the cadherin complex is not known. Interestingly, two high throughput two-hybrid studies detected a binding interaction between TRIP6 and the adherens junction protein vinculin (Rual et al., 2005; Yu et al., 2011) . Consistent with the high throughput studies, we detected vinculin in TRIP6 immune-complexes ( Figure 5A ). Vinculin and TRIP6 are known to respond to mechanical cues at focal adhesions (Bays and DeMali, 2017; Kuo et al., 2011; Schiller et al., 2011) and vinculin localization to adherens junctions depends on myosin contractile activity (Yonemura et al., 2010) . As with TRIP6, we observed vinculin at focal adhesions in MCF10A cells at low density or at the edge of monolayers, but at densities used in this study (confluent but still proliferating), vinculin was concentrated at adherens junctions ( Figure S5A ). Thus, we infer that TRIP6 is primarily interacting with vinculin at adherens junctions under these conditions. At high cell density vinculin localization to adherens junctions was lost, but could be restored by stretch ( Figure 5B -C), as observed for TRIP6 and LATS1. Vinculin localization to adherens junctions and binding to TRIP6 is reduced by treatments that disrupt tension ( Figure 5B , 5D, S5B). In addition, when vinculin levels were reduced by siRNA, TRIP6-LATS1 binding and localization to cell-cell junctions were inhibited (Figure 5E-F; S5C-D). Depletion of vinculin also reduced YAP nuclear localization and activity (as judged by reduction in YAP target gene (CTGF and Cyr61) expression in MCF10A cells . This same effect on YAP was observed using two different siRNAs ( Figure S5E-F) . Knockdown of vinculin in HEK293A cells also reduced YAP activity (S5G) and this reduction could be rescued by expression of vinculin ( Figure S5G -H). Together these results show that tension stimulates vinculin recruitment to adherens junctions and binding to TRIP6. Vinculin promotes TRIP6-LATS1/2 binding and localization to adherens junctions to control YAP activity in response to changes in tension across tissues.
Discussion
This study provides new insight into the mechanism by which mechanical forces regulate cell growth and proliferation decisions via the Hippo signaling pathway. In particular, we report that the LIM domain protein TRIP6 functions as an intermediate between the LATS1/2 protein kinases, which transmit signals to YAP, and the mechano-responsive protein vinculin at the adherens junctions. Previous studies have shown that YAP activity can be stimulated by tension (Aragona et al., 2013; Benham-Pyle et al., 2015; Codelia et al., 2014; Rauskolb et al., 2014) , however, the upstream signaling pathways remained uncertain. We found that tension stimulates TRIP6 binding to LATS1/2, and, once bound, TRIP6 inhibits LATS1/2 activity, reminiscent of work in Drosophila showing that the Ajuba LIM domain protein activates Yki (the YAP homolog) by inhibiting Warts (the LATS1/2 homolog) in response to tension (Rauskolb et al., 2014) . Furthermore, we identified a specific molecular mechanism for how TRIP6 inhibits LATS1/2. We discovered that TRIP6 competes with MOB1 for binding to LATS1/2. MOB1 promotes LATS1/2 activation by scaffolding interactions between the LATS1/2 activating kinase MST1/2 and LATS1/2. The competition we observe between TRIP6 and MOB1 for binding to LATS1/2 is consistent with our other results showing TRIP6 interferes with MST1/2 phosphorylation of LATS1/2. This mechanism may be relevant for other LIM domain proteins that bind to a similar region of LATS1/2 (Abe et al., 2006; Hirota et al., 2000) , and could function in conjunction with other proposed mechanisms for how LIM domain proteins inhibit LATS1/2 (Jagannathan et al., 2016; Ma et al., 2016; Sun et al., 2015) .
Our studies identified vinculin as acting upstream of TRIP6. Both TRIP6 and vinculin loss of function inhibits YAP activity, vinculin binds TRIP6, and is required to recruit TRIP6 and LATS1/2 to adherens junctions and promote their binding to each other. It is not clear how vinculin promotes TRIP6-LATS binding, but one possibility is that vinculin directly or indirectly causes a conformational change in TRIP6 to allow it to bind LATS1/2. Vinculin itself responds to mechanical tension at adherens junctions since both vinculin localization to adherens junctions and vinculin-TRIP6 binding is dependent on mechanical tension. Previous studies have shown that vinculin is recruited to adherens junctions by α-catenin, which responds directly to mechanical tension. Alphacatenin binding to vinculin stabilizes its open conformation allowing it to bind actin and possibly other effectors like TRIP6 (Choi et al., 2012; Huveneers and de Rooij, 2013; Twiss et al., 2012; Yonemura et al., 2010) . The open conformation of vinculin induced by α-catenin may stimulate vinculin binding to TRIP6. If this was the case then one would expect α-catenin and vinculin loss of function to have similar effects on YAP activity. However, previous studies showed that α-catenin loss of function stimulates YAP activity (Kim et al., 2011; Schlegelmilch et al., 2011; Silvis et al., 2011) , in contrast to the increased YAP activity we observe when vinculin is knocked down. This apparent discrepancy could be resolved if adherens junctions and α-catenin had different functions in cells at lower density (higher tension) compared to cells at high density (low tension). It should be noted that the earlier studies showing α-catenin acting as an inhibitor of YAP were done at high cell density where tension would be low and vinculin and TRIP6 would not be at adherens junctions. At lower cell density, when cells are confluent but still proliferating (and presumably under more tension), α-catenin may recruit vinculin to adherens junctions to enhance YAP activity (via TRIP6 inhibition of LATS1/2) and drive cell proliferation. Thus, as cell density increases and tension decreases the vinculin-TRIP6 system turns off, and the YAP inhibitory function of adherens junctions could become dominant. It will be interesting in the future to determine how these two systems interact with each other to tune YAP regulation in response to changes in cell density and/or tension. In summary, we showed that TRIP6 acts as an intermediary connecting tension monitoring at adherens junctions to Hippo signaling, which has implications for how tension contributes to growth of organs and tissues during development, tissue repair during injury and to pathological conditions such as cancer. by the National Institutes of Health grant GM058406-18 to DM, and a UMMS-WPI seed grant to DM and KB. or a mix of two different shRNA against TRIP6 (shTRIP6-1 and shTRIP6-4) and were stained for TRIP6 and LATS1. Merged images show LATS1 (green), TRIP6 (red) and DNA (blue) (quantification of LATS1 localization at cell-cell junctions is shown in Figure S3D ). Scale bar=20µm. (B) LATS1 and LATS2 were knocked down using siLATS1 and siLATS2 SMARTPools in MCF10A cells. MCF10A control cells were treated with control siRNA (siControl) against fire fly luciferase. Cells were stained for TRIP6 and LATS1 as in (A) (quantification of TRIP6 localization at cell-cell junctions is shown in Figure S3E ). Scale bar=20µm. (C) MCF10A cells were grown to high density, and were stained for TRIP6 and LATS1 as in (A). Scale bar=20µm. (D) Cells were grown as in (C), then lysed and anti-TRIP6 or control (IgG) antibodies were used to isolate immune complexes. Immune complexes and lysates were probed by western blotting for LATS1 and TRIP6. Quantification is shown. (Mean ± SD; n=3; *P≤0.05, T-test). (E) MCF10A cells grown at high density on PDMS membranes and were stretched (or not) at 17% elongation for 2 hours and lysed while under tension. Anti-TRIP6 or control (IgG) antibodies were used to isolate immune complexes. Immune complexes and lysates were probed by western blotting for LATS1 and TRIP6. Quantification is shown. (Mean ± SD; n=3; *P≤0.05, T-test). (F) Cells were treated as in (E), fixed while under tension, and stained for TRIP6 and LATS1 as in (A). Scale bar=20µm. (G) MCF10A cells infected with lentivirus carrying control shRNA (shEGFP), or a mix of two different shRNA against TRIP6 (shTRIP6-1 and shTRIP6-4), were grown at high density on PDMS membranes and were stretched or not (only stretched cells shown) at 17% elongation for 2 hours, fixed while under tension, and were stained for TRIP6 and LATS1 as in (A). Scale bar=20µm. (H) Cells were treated as in (G) and YAP target gene (CTGF and Cyr61) and TRIP6 expression were analyzed using RT-qPCR. (Mean ± SD; n=3; *P≤0.05, **P≤0.01, T-test). Vinculin regulates TRIP6-LATS1 interaction, localization, and YAP activity. (A) MCF10A cells were lysed and anti-TRIP6 or control (IgG) antibodies were used to isolate immune complexes. Immune complexes and lysates were probed by western blotting for vinculin and TRIP6. (B) MCF10A cells were either not treated (control) or treated separately by growth to high density, serum starvation, Latrunculin B, Blebbistatin, EGTA, or Y27632 treatment, and stained using antivinculin antibodies by immunofluorescence. Scale bar=20µm. (C) MCF10A cells grown at high density on PDMS membranes and were stretched (or not) at 17% elongation for 2 hours and fixed while under tension and stained for vinculin. Scale bar=20µm. (D) MCF10A cells were subjected to different treatments as described in Figure 4A and TRIP6 immune complexes and lysates were probed by western blotting for vinculin and TRIP6 (quantification is shown in Figure  S5B ). (E) Vinculin was knocked down using two different siRNAs or control siRNA in MCF10A cells and cells were stained for LATS1 and TRIP6. Merged images show LATS1 (green), TRIP6 (red) and DNA (blue). Scale bar=20µm. (F) Vinculin was knocked down as described in (E) and TRIP6 immune complexes and lysates were probed by western blotting for LATS1 and TRIP6 and the relative levels quantified (Mean ± SD; n=3; **P≤0.01, T-test). (G) Vinculin was knocked down as described in (E) and cells were stained for YAP and TRIP6. Merged image shows YAP (green), TRIP6 (red), and DNA (blue). Quantification of at least 100 cells is shown (Mean ± SD; n=3; ***P≤0.001, Fisher's test). Scale bar=20µm. (H) Vinculin was knocked down as described in (E) and the levels of vinculin and YAP target gene expression was analyzed using RT-qPCR (Mean ± SD; n=3; ***P≤0.001, ****P≤0.0001, T-test). Figure S1 . TRIP6 knockdown in MCF10A cells activates hippo signaling and TRIP6∆ knockout cells are rescued by FLAG-TRIP6 expression. (A) Lysates from MCF10A cells infected with control lentivirus (shEGFP) or lentivirus expressing shRNA against TRIP6 (shTRIP6) were analyzed by western blotting using the indicated antibodies, and the levels of LATS1 activating phosphorylation was quantified (Mean ± SD; n=3; **P≤0.01, T-test). (B) MCF10A cells were infected with lentivirus carrying control shRNA (shEGFP), or two different shRNA against TRIP6 (shTRIP6-1, shTRIP6-4) and the levels of TRIP6 and YAP target gene expression was analyzed using RT-qPCR (Mean ± SD; n=3; **P≤0.01, ***P≤0.001, T-test). (C) MCF10A cells were infected with lentivirus carrying control shRNA (shEGFP), or a mix of two different shRNA against TRIP6 (shTRIP6-1 and shTRIP6-4) and were stained for YAP and TRIP6. Merged image shows YAP (green), TRIP6 (red), and DNA (blue). Quantification of YAP nuclear localization is shown (Mean ± SD; n=3; ****P≤0.0001, Fisher's test (50, 100, 150, 200ng) of FLAG-TRIP6 plasmid were transfected into HEK293A TRIP6Δ cells and TRIP6 levels in lysates were analyzed by western blotting using anti-TRIP6 antibodies and compared to those in control HEK293A (WT) cells. 200ng of FLAG-TRIP6 plasmid (marked with asterisk) was selected to perform the rescue experiment described in (E).
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Supplemental Figures
Figure S2.
Coomassie stained gel showing the amounts of BSA and highest amount of HIS-MOB1A used in Figure 2B . Figure 3A) . Intensity of LATS1 was measured at cell-cell junctions (Mean ± SD; n=3; **P≤0.01, T-test). (E) Quantification of TRIP6 at cell-cell junctions in MCF10A depleted of LATS1 and LATS2 (see Figure 3B ). Intensity of TRIP6 was measured at cell-cell junctions (Mean ± SD; n=3; n.s.≥0.05, T-test). (F) MCF10A cells grown at high density on PDMS membranes and were stretched (or not) at 17% elongation for 2 hours, RNA was isolated and YAP target gene expression was analyzed using RT-qPCR. (Mean ± SD; n=3; **P≤0.01, ****P≤0.0001, T-test).
Figure S4.
Regulation of TRIP6 and LATS1 localization in HEK293A cells and E-cadherin staining in MCF10A cells after various treatments. (A) HEK293A cells were either not treated (control) or treated separately by serum starvation (no serum), Latrunculin B, Blebbistatin, and EGTA, then TRIP6 and LATS1 intracellular localization were determined by immunofluorescence using anti-TRIP6 and anti-LATS1 antibodies. The localization of TRIP6 and LATS1 in HEK293A TRIP6Δ cells is also shown. Scale bar=20µm. (B) MCF10A cells were either not treated (control) or treated separately by growth to high density, serum starvation, Latrunculin B, Blebbistatin, or Y27632 treatment, and stained using anti-Ecadherin antibodies by immunofluorescence. Scale bar=20µm. (50, 150, 250, 350ng) of EGFP-vinculin plasmid were transfected into the vinculin depleted cells and vinculin levels in lysates were analyzed by western blotting using anti-vinculin antibody and compared to those in control HEK293A cells. 150ng of EGFP-vinculin plasmid (marked with asterisk) was selected to perform the rescue experiment.
Table S1
Table S1 consists of a list of qPCR primers and primers for CRISPR mediated TRIP6 knockout in HEK293A cells. 
